Angiotensin II, tissue factor and the thrombotic paradox of hypertension

References

• Lip GY. Hypertension, platelets, and the endothelium. The ‘thrombotic paradox’ of hypertension (or ‘Birmingham paradox’) revisited. Hypertension41, 199–200 (2003).
   PubMed Web of Science ®Google Scholar
• Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol.27, 1687–1693 (2007).
   PubMed Web of Science ®Google Scholar
• Laragh JH, Sealey JE. The renin–angiotensin–aldosterone system in hypertensive disorders: a key to two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In: Hypertension. Pathophysiology, Diagnosis and Management. Laragh JH, Brenner BM (Eds). Raven Press Ltd, NY, USA, 1329–1348 (1990).
   Google Scholar
• Celi A, Lorenzet R, Furie BC, Furie B. Microparticles and a P-selectin-mediated pathway of blood coagulation. Dis. Markers20, 347–352 (2004).
   PubMed Web of Science ®Google Scholar
• Halvorsen H, Olsen JO, Osterud B. Granulocytes enhance LPS-induced tissue factor activity in monocytes via an interaction with platelets. J. Leukoc. Biol.54, 275–282 (1993).
   PubMed Web of Science ®Google Scholar
• Camera M, Frigerio M, Toschi V et al. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler. Thromb. Vasc. Biol.23, 1690–1696 (2003).
   PubMed Web of Science ®Google Scholar
• Maugeri N, Brambilla M, Camera M et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J. Thromb. Haemost.4, 1323–1330 (2006).
   PubMed Web of Science ®Google Scholar
• Egorina EM, Sovershaev MA, Olsen JO, Osterud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood. Evidence for a direct transfer. Blood111, 1208–1216 (2008).
   PubMed Web of Science ®Google Scholar
• Lechner D, Weltermann A. Circulating tissue factor-exposing microparticles. Thromb. Res.122(Suppl. 1), S47–S54 (2008).
   PubMed Web of Science ®Google Scholar
• Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb. Haemost.97, 714–721 (2007).
   PubMed Web of Science ®Google Scholar
• Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases. molecular mechanisms and clinical implications. Circulation113, 722–731 (2006).
   PubMed Web of Science ®Google Scholar
• Marmur JD, Rossikhina M, Guha A et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J. Clin. Invest.91, 2253–2259 (1993).
   PubMed Web of Science ®Google Scholar
• Wu J, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells. mechanisms and in vivo significance. Arterioscler. Thromb. Vasc. Biol.28, 698–704 (2008).
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation109, 2698–2704 (2004).
   PubMed Web of Science ®Google Scholar
• Lehoux S, Tedgui A. Signal transduction of mechanical stresses in the vascular wall. Hypertension32, 338–345 (1998).
   PubMed Web of Science ®Google Scholar
• Ungvari Z, Wolin MS, Csiszar A. Mechanosensitive production of reactive oxygen species in endothelial and smooth muscle cells: role in microvascular remodeling? Antioxid. Redox Signal.8, 1121–1129 (2006).
   PubMed Web of Science ®Google Scholar
• Balligand JL, Feron O, Dessy C. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiol. Rev.89, 481–534 (2009).
   PubMed Web of Science ®Google Scholar
• Nestoridi E, Kushak RI, Tsukurov O, Grabowski EF, Ingelfinger JR. Role of the renin angiotensin system in TNF-α and Shiga-toxin-induced tissue factor expression. Pediatr. Nephrol.23, 221–231 (2008).
   PubMed Web of Science ®Google Scholar
• Shang MH, Yuan WJ, Zhang SJ, Fan Y, Zhang Z. Intrarenal activation of renin angiotensin system in the development of cyclosporine A induced chronic nephrotoxicity. Chin. Med. J.121, 983–988 (2008).
   PubMed Web of Science ®Google Scholar
• Griendling KK, Ushio-Fukai M, Lassègue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension29(Pt 2), 366–373 (1997).
   PubMed Web of Science ®Google Scholar
• Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler. Thromb. Vasc. Biol.20, 2175–2183 (2000).
   PubMed Web of Science ®Google Scholar
• Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest.90, 278–281 (1992).
   PubMed Web of Science ®Google Scholar
• Corseaux D, Ollivier V, Fontaine V et al. Hemostasis imbalance in experimental hypertension. Mol. Med.8, 169–178 (2002).
   PubMed Web of Science ®Google Scholar
• Müller DN, Mervaala EM, Dechend R et al. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am. J. Pathol.157, 111–122 (2000).
   PubMed Web of Science ®Google Scholar
• Muller DN, Mervaala EM, Schmidt F et al. Effect of bosentan on NF-κB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension36, 282–290 (2000).
   PubMed Web of Science ®Google Scholar
• Felmeden DC, Spencer CG, Chung NA et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo–Scandinavian Cardiac Outcomes Trial [ASCOT]). Am. J. Cardiol.92, 400–405 (2003).
   PubMed Web of Science ®Google Scholar
• Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann KG. Immunologic quantitation of tissue factors. J. Thromb. Haemost.4, 1747–1755 (2006).
   PubMed Web of Science ®Google Scholar
• Sardo MA, Campo S, Mandraffino G et al. Tissue factor and monocyte chemoattractant protein-1 expression in hypertensive individuals with normal or increased carotid intima–media wall thickness. Clin. Chem.54, 814–823 (2008).
   PubMed Web of Science ®Google Scholar
• Boulanger CM. Microparticles, vascular function and hypertension. Curr. Opin. Nephrol. Hypertens.19, 177–180 (2010).
   PubMed Web of Science ®Google Scholar
• Preston RA, Jy W, Jimenez JJ et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension41, 211–217 (2003).
   PubMed Web of Science ®Google Scholar
• Huang PH, Huang SS, Chen YH et al. Increased circulating CD31+/annexin V+ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J. Hypertens.28, 1655–1665 (2010).
   PubMed Web of Science ®Google Scholar
• Helal O, Defoort C, Robert S et al. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome. Relationship with oxidative stress. Nutr. Metab. Cardiovasc. Dis. DOI: 10.1016/j.numecd.2010.01.004 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Combes V, Simon AC, Grau GE et al.In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J. Clin. Invest.104, 93–102 (1999).
   PubMed Web of Science ®Google Scholar
• Giannotti G, Doerries C, Mocharla PS et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension. Relation to endothelial dysfunction. Hypertension55, 1389–1397 (2010).
   PubMed Web of Science ®Google Scholar
• Meade TW, Mellows 5, Brozovic M et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet2, 533–537 (1986).
   PubMed Web of Science ®Google Scholar
• Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin–angiotensin systems. Physiol. Rev.86, 747–803 (2006).
   PubMed Web of Science ®Google Scholar
• Mackman N. Regulation of the tissue factor gene. Thromb. Haemost.78, 747–754 (1997).
   PubMed Web of Science ®Google Scholar
• Moynagh PN. The NF-κB pathway. J. Cell. Sci.118, 4589–4592 (2005).
   PubMedGoogle Scholar
• He M, He X, Xie Q, Chen F, He S. Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes. Thromb. Res.117, 579–590 (2006).
   PubMed Web of Science ®Google Scholar
• Nishimura H, Tsuji H, Masuda H et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb. Haemost.77, 1189–1195 (1997).
   PubMed Web of Science ®Google Scholar
• Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. Role of Ca2+ mobilization and protein kinase C activation. J. Clin. Invest.91, 547–552 (1993).
   PubMed Web of Science ®Google Scholar
• Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ. Res.86, 139–143 (2000).
   PubMed Web of Science ®Google Scholar
• Maibaum J, Stutz S, Göschke R et al. Structural modification of the P2’ position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides. The discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets. J. Med. Chem.50, 4832–4844 (2007).
   PubMed Web of Science ®Google Scholar
• Del Fiorentino A, Cianchetti S, Celi A, Pedrinelli R. Aliskiren, a renin inhibitor, downregulates TNF-{α}-induced tissue factor expression in HUVECS. J. Renin Angiotensin Aldosterone Syst. DOI: 10.1177/1470320310379449 (2010) (Epub ahead of print).
   Google Scholar
• Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension51, 1306–1311 (2008).
   PubMed Web of Science ®Google Scholar
• Ino J, Kojima C, Osaka M, Nitta K, Yoshida M. Dynamic observation of mechanically-injured mouse femoral artery reveals an antiinflammatory effect of renin inhibitor. Arterioscler. Thromb. Vasc. Biol.29, 1858–1863 (2009).
   PubMed Web of Science ®Google Scholar
• Del Fiorentino A, Cianchetti S, Celi A, Dell’Omo G, Pedrinelli R. The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. Vasc. Health. Risk. Manag.5, 233–242 (2009).
   PubMedGoogle Scholar
• Dechend R, Homuth V, Wallukat G et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation101, 2382–2387 (2000).
   PubMed Web of Science ®Google Scholar
• von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence. Circulation.89, 458–470 (1994).
   PubMed Web of Science ®Google Scholar
• Pawlinski R, Wang JG, Owens AP 3rd et al. Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood116, 806–814 (2010).
   PubMedGoogle Scholar
• Atkinson BT, Jasuja R, Chen V, Nandivada P, Furie B, Furie BC. Laser-induced endothelial cell activation supports fibrin formation. Blood DOI: 10.1182/blood-2010-05-283986 (2010) (Epub ahead of print).
   Google Scholar
• Koh KK, Chung WJ, Ahn JY et al. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients. A randomized, double-blind, placebo-controlled study. Atherosclerosis177, 155–160 (2004).
   PubMed Web of Science ®Google Scholar
• Berman CL, Yeo EL, Wencel-Drake JD, Furie BC, Ginsberg MH, Furie B. A platelet α granule membrane protein that is associated with the plasma membrane after activation. Characterization and subcellular localization of platelet activation-dependent granule-external membrane protein. J. Clin. Invest.78, 130–137 (1986).
   PubMed Web of Science ®Google Scholar
• Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a component of Weibel–Palade bodies of human endothelial cells. Blood73, 1109–1112 (1989).
   PubMed Web of Science ®Google Scholar
• Larsen E, Celi A, Gilbert GE et al. PADGEM protein. A receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell59, 305–312 (1989).
   PubMed Web of Science ®Google Scholar
• Geng JG, Bevilacqua MP, Moore KL et al. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature343, 757–760 (1990).
   PubMed Web of Science ®Google Scholar
• Wagner DD. P-selectin chases a butterfly. J. Clin. Invest.95, 1955–1956 (1995).
   PubMed Web of Science ®Google Scholar
• Celi A, Pellegrini G, Lorenzet R et al. P-selectin induces the expression of tissue factor on monocytes. Proc. Natl Acad. Sci. USA91, 8767–8771 (1994).
   PubMed Web of Science ®Google Scholar
• Blann AD, Nadar S, Lip GY. Pharmacological modulation of platelet function in hypertension. Hypertension42, 1–7 (2003).
   PubMed Web of Science ®Google Scholar